Monte Rosa Therapeutics (GLUE) Operating Income (2020 - 2026)

Monte Rosa Therapeutics' Operating Income history runs 7 years deep, the most recent figure standing at -$50.0 million for Q1 2026.

• In Q1 2026, Operating Income fell 213.62% year-over-year to -$50.0 million; the TTM figure through Mar 2026 stood at -$102.4 million (down 4708.74% YoY), while the FY2025 annual figure was -$8.3 million, up 89.76% from the prior year.
• Operating Income was -$50.0 million for Q1 2026 at Monte Rosa Therapeutics, down from -$3.8 million in the prior quarter.
• In the past five years, Operating Income ranged from a high of $44.0 million in Q1 2025 to a low of -$50.0 million in Q1 2026.
• Historically, Operating Income has averaged -$23.2 million across 5 years, with a median of -$32.5 million in 2022.
• The sharpest annual moves came in 2025 and 2026: Operating Income surged 226.01% in 2025, then sank 213.62% in 2026.
• A 5-year view of Operating Income shows it stood at -$32.5 million in 2022, then decreased by 7.31% to -$34.9 million in 2023, then surged by 137.3% to $13.0 million in 2024, then slumped by 129.34% to -$3.8 million in 2025, then plunged by 1211.51% to -$50.0 million in 2026.
• The last three Operating Income figures came in at -$50.0 million (Q1 2026), -$3.8 million (Q4 2025), and -$33.0 million (Q3 2025), per Business Quant data.